HCWB

HCW Biologics Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat cancer and age-related diseases. Headquartered in Miramar, Florida, the company leverages its proprietary TOBI (Twin Opposite Biospecific Immunomodulator) platform to engineer multi-functional biologics that simultaneously activate immune effector cells and block immune inhibitory cells. The company's lead product candidate, HCW9218, is a bifunctional protein designed to stimulate T-cells while blocking immunosuppressive regulatory T-cells for treating various solid tumors. HCW9206, another key pipeline asset, targets age-related conditions by activating the GDF15 and FGF21 pathways. HCW Biologics operates a manufacturing facility in Miramar capable of producing clinical and commercial-scale biologics using proprietary yeast-based expression systems. The company went public in July 2021 through an initial public offering on the Nasdaq under the ticker symbol HCWB. In recent developments, HCW Biologics has advanced multiple programs through early-stage clinical trials and continues to expand its pipeline through internal research and development. The company's approach differentiates itself through its ability to produce complex biologics at potentially lower costs compared to traditional mammalian cell-based manufacturing, while creating multi-functional therapeutic proteins designed to overcome limitations of single-target immunotherapies.